Dupilumab is a fully human IgG4 monoclonal antibody directed against the interleukin-4 receptor subunit α (IL-4Rα) of the IL-4 and IL-13 receptors and has been approved in some countries and regions for the treatment of patients with moderate to severe AD. The gene discussed is IL4; the disease is Alzheimer disease.